PCMI
VRTX icon

Princeton Capital Management Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Princeton Capital Management Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$3.44M Buy
22,609
+1,639
+8% +$247K 1.74% 23
2017
Q2 		$2.7M Sell
20,970
-1,502
-7% -$181K 1.7% 25
2017
Q1 		$2.46M Sell
22,472
-1,324
-6% -$117K 1.55% 25
2016
Q4 		$1.75M Sell
23,796
-1,753
-7% -$143K 1.17% 31
2016
Q3 		$2.23M Buy
25,549
+227
+0.9% +$21.5K 1.46% 28
2016
Q2 		$2.18M Buy
25,322
+45
+0.2% +$3.89K 1.5% 24
2016
Q1 		$2.01M Buy
25,277
+309
+1% +$27.9K 1.39% 28
2015
Q4 		$3.14M Sell
24,968
-1,157
-4% -$140K 2.21% 22
2015
Q3 		$2.72M Sell
26,125
-2,536
-9% -$326K 1.65% 28
2015
Q2 		$3.54M Sell
28,661
-610
-2% -$76.9K 1.87% 26
2015
Q1 		$3.45M Sell
29,271
-1,360
-4% -$163K 1.77% 27
2014
Q4 		$3.64M Buy
30,631
+555
+2% +$62.5K 2.01% 23
2014
Q3 		$3.38M Sell
30,076
-290
-1% -$27.6K 2.15% 20
2014
Q2 		$2.88M Buy
30,366
+2,640
+10% +$185K 1.99% 22
2014
Q1 		$1.96M Buy
27,726
+1,480
+6% +$117K 1.42% 29
2013
Q4 		$1.95M Sell
26,246
-1,009
-4% -$70.3K 1.56% 26
2013
Q3 		$2.07M Sell
27,255
-720
-3% -$57.3K 1.89% 22
2013
Q2 		$2.24M Buy
+27,975
New +$2.06M 2.15% 18

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Princeton Capital Management Inc's VRTX Position: Q3 2017 in Review

Princeton Capital Management Inc increased its Vertex Pharmaceuticals (VRTX) stake by 7.8% in Q3 2017, buying an estimated $247K and bringing the position to 22,609 shares worth $3.44M. The position accounts for 1.74% of the portfolio, ranked #23.

Princeton Capital Management Inc first reported a position in VRTX in Q2 2013 and has held it in 18 quarters since. The position peaked at $3.64M in Q4 2014. 611 funds tracked by Wall St. Rank hold VRTX as of Q3 2017.

  • Princeton Capital Management Inc held 22,609 shares of Vertex Pharmaceuticals worth $3.44M as of Q3 2017.
  • Princeton Capital Management Inc bought 1,639 Vertex Pharmaceuticals shares in Q3 2017, an estimated $247K.
  • Vertex Pharmaceuticals made up 1.74% of Princeton Capital Management Inc's portfolio in Q3 2017, its #23 holding.
  • Princeton Capital Management Inc first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
  • Princeton Capital Management Inc's Vertex Pharmaceuticals position peaked at $3.64M in Q4 2014.
  • 611 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2017.

Based on Princeton Capital Management Inc's 13F filing for Q3 2017, filed 3 Nov 2017.